查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1540794

2024-2032 年藥物警戒市場報告（按服務提供者、產品生命週期、類型、流程、治療領域、最終用途和地區分類）

Pharmacovigilance Market Report by Service Provider, Product Life Cycle, Type, Process Flow, Therapeutic Area, End Use, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年全球藥物警戒市場規模達79億美元。藥物不良反應（ADR）的日益普遍，加上政府機構推出有利政策以提高人們對正確使用藥物的認知並進行臨床試驗，主要刺激了藥物警戒市場的成長。

全球藥物警戒市場分析：

主要市場促進因素：各種生活方式疾病（包括心臟病、高血壓、糖尿病等）發病率的上升正在增加全球藥物的使用。因此，對藥物警戒（PV）的需求不斷增加，以檢測以前未知的不良反應，識別頻率或嚴重程度的變化，評估藥物的風險和益處以確定所需的行動等。的機會藥物警戒市場前景。

主要市場趨勢：藥物警戒市場的主要趨勢之一包括開發先進平台以確保自動報告藥物不良反應 (ADR)。此外，由於競爭環境，主要參與者也專注於加強製造業務和簡化研發活動。除此之外，臨床試驗數量的增加預計將在預測期內推動藥物警戒市場的發展。

競爭格局：一些著名的藥物警戒市場主要參與者包括Accenture plc、ArisGlobal LLC、BioClinica Inc. (Cinven Partners LLP)、Capgemini、Cognizant、International Business Machines Corporation、ICON plc.、IQVIA Inc.、ITClinical、Parexel International Corporation 、及 Wipro Limited 等。

挑戰與機會：根據藥物警戒市場分析，一些挑戰包括政府機構嚴格的監管要求、管理和從大量資料中獲取有意義的見解的複雜性不斷增加，以及平衡全面藥物安全監測的需求日益增加控制成本的壓力正在阻礙全球藥物警戒產業的成長。然而，促進策略合作以確保藥品安全和維護公眾健康預計將在未來幾年推動藥物警戒市場佔有率的成長。

全球藥物警戒市場趨勢：

技術不斷進步的發展

機器學習 (ML)、自然語言處理 (NLP)、人工智慧 (AI)、巨量資料分析等新技術的日益整合正在增強藥物警戒流程。與此一致，這些技術正在獲得廣泛的關注，因為它們有助於識別不良事件、風險評估、實現有效的訊號檢測等，預計這將在預測期內推動市場成長。例如，賽諾菲和德勤合作開發了ConvergeHEALTH Safety，這是下一代人工智慧(AI) 軟體即服務不良事件案例受理平台，該平台改變了藥物警戒(PV) 流程並解決了行業中一些最緊迫的操作安全問題。為此，ArisGlobal 推出了 USFDA 不良事件報告系統 (FAERS II)，這是一個由 LifeSphere MultiVigilance 提供支援的電子安全報告平台，推動了市場成長。此外，Saama Technologies Inc. 開發了新的製藥主動安全分析 (ASAP) 產品。 ASAP 是首批經過驗證的藥物警戒解決方案之一，利用 TreeScan 方法和美國食品藥物管理局 (FDA) 的哨兵通用資料模型來檢測安全訊號。

政府機關實施嚴格的法規

全球各地的政府當局正在臨床試驗中實施嚴格的規則，並提高人們對正確使用藥物的認知，這正在刺激藥物警戒服務的使用。例如，根據《藥物安全與監管前沿》發表的一項研究，上市後藥物評估的重要性對於描述現實環境中的藥物安全狀況非常重要。此類研究進一步提高了藥物警戒的重要性，從而刺激了市場成長。此外，由於存在 N-亞硝基喹那普利和亞硝胺藥物相關雜質 (NDSRI)，Aurobindo Pharma USA 重新配製了喹那普利和氫氯噻嗪片 USP 20mg/12.5mg。因此，監管機構對醫療資訊日益成長的需求預計將推動預測期內的市場成長。

製藥公司擴大採用藥物警戒服務

藥物警戒服務因其優勢（例如在更短的時間內獲得更好的結果以及提高內部資源靈活性）而被全球主要製藥公司廣泛採用。例如，根據疫苗不良事件通報系統的數據，在注射了 4,041,396 劑 Moderna COVID-19 疫苗後，發現了 10 例過敏反應病例（每百萬劑中有 2.5 例）。因此，對藥物警戒服務不斷成長的需求也刺激了市場的成長。除此之外，主要產業參與者也正在進行策略合作，這將在預測期內繼續推動藥物警戒市場的發展。例如，IQVIA 與 NRx Pharmaceuticals 達成策略合作，提供醫療資訊和藥物警戒服務，為潛在的監管行動做好準備。

高級臨床試驗階段的數量不斷增加

為了提高臨床試驗的功效，主要參與者正在開發先進的臨床試驗，這正在刺激全球藥物警戒市場。例如，Cognizant 與 Medable Inc. 建立合作關係，共同提供基於 Medable 的軟體即服務平台的臨床研究解決方案，用於分散式臨床試驗。據此，根據藥物警戒市場概況，Viedoc 與 LINK Medical 建立了 Viedoc 建立的合作關係。此次合作旨在提高 LINK Medical 及其客戶的試驗效率。這種夥伴關係允許交流需求、經驗、想法等，並測試新功能。

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球藥物警戒市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：按服務提供者

  • 內部
    • 市場趨勢
    • 市場預測
  • 合約外包
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：依產品生命週期

  • 臨床前
    • 市場趨勢
    • 市場預測
  • 第一階段
    • 市場趨勢
    • 市場預測
  • 第二階段
    • 市場趨勢
    • 市場預測
  • 第三階段
    • 市場趨勢
    • 市場預測
  • 第四階段
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：按類型

  • 自發性報告
    • 市場趨勢
    • 市場預測
  • 強化 ADR 報告
    • 市場趨勢
    • 市場預測
  • 針對性的自發性報告
    • 市場趨勢
    • 市場預測
  • 群組事件監控
    • 市場趨勢
    • 市場預測
  • 電子病歷採礦
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：依製程流程

  • 案例資料管理
    • 市場趨勢
    • 主要類型
      • 案例記錄
      • 案例數據分析
      • 醫學審查和報告
    • 市場預測
  • 訊號檢測
    • 市場趨勢
    • 主要類型
      • 不良事件記錄
      • 不良事件分析
      • 不良事件審查和報告
    • 市場預測
  • 風險管理系統
    • 市場趨勢
    • 主要類型
      • 風險評估體系
      • 風險緩釋系統
    • 市場預測

第 10 章：市場區隔：依治療領域

  • 腫瘤學
    • 市場趨勢
    • 市場預測
  • 神經病學
    • 市場趨勢
    • 市場預測
  • 心臟病學
    • 市場趨勢
    • 市場預測
  • 呼吸系統
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 11 章：市場區隔：最終用途別

  • 製藥公司
    • 市場趨勢
    • 市場預測
  • 生技公司
    • 市場趨勢
    • 市場預測
  • 醫療器材公司
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 12 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 13 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 14 章：價值鏈分析

第 15 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 16 章：價格分析

第17章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Accenture plc
    • ArisGlobal LLC
    • BioClinica Inc. (Cinven Partners LLP)
    • Capgemini
    • Cognizant
    • International Business Machines Corporation
    • ICON plc.
    • IQVIA Inc.
    • ITClinical
    • Parexel International Corporation
    • Wipro Limited
Product Code: SR112024A3609

The global pharmacovigilance market size reached US$ 7.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 15.9 Billion by 2032, exhibiting a growth rate (CAGR) of 7.8% during 2024-2032. The increasing prevalence of adverse drug reactions (ADRs), coupled with the launch of favorable policies by government bodies to generate awareness about the proper usage of medicines and conduct clinical trials, is primarily stimulating the pharmacovigilance market growth.

Global Pharmacovigilance Market Analysis:

Major Market Drivers: The elevating incidences of various lifestyle diseases, including cardiac disorders, hypertension, diabetes, etc., are augmenting the usage of drugs across the globe. Consequently, there is an elevating need for pharmacovigilance (PV) to detect previously unknown adverse effects, recognize changes in the frequency or severity, assess the risks and benefits of drugs to determine required actions, etc. This, in turn, is providing significant opportunities in the pharmacovigilance market outlook.

Key Market Trends: One of the key pharmacovigilance market trends includes the development of advanced platforms to ensure automated adverse drug reactions (ADR) reporting. Furthermore, key players are also focusing on enhancing manufacturing operations and streamlining R&D activities, owing to the competitive environment. Besides this, the rising number of clinical trials is expected to fuel the pharmacovigilance market in the forecasted period.

Competitive Landscape: Some of the prominent pharmacovigilance market key players are Accenture plc, ArisGlobal LLC, BioClinica Inc. (Cinven Partners LLP), Capgemini, Cognizant, International Business Machines Corporation, ICON plc., IQVIA Inc., ITClinical, Parexel International Corporation, and Wipro Limited, among many others.

Challenges and Opportunities: According to the pharmacovigilance market analysis, some of the challenges, including stringent regulatory requirements by government bodies, the rising complexities in managing and deriving meaningful insights from a vast amount of data, and the increasing need for balancing comprehensive drug safety monitoring with the pressure to control costs, are hindering the growth of the pharmacovigilance industry across the globe. However, fostering strategic collaborations to ensure the safety of drugs and safeguard public health is expected to propel the pharmacovigilance market share in the coming years.

Global Pharmacovigilance Market Trends:

The Development of Continuous Technological Advancements

The increasing integration of novel technologies, such as machine learning (ML), natural language processing (NLP), artificial intelligence (AI), big data analytics, etc., is enhancing the pharmacovigilance processes. In line with this, these technologies are gaining extensive traction, as they help in identifying adverse events, risk assessments, enabling efficient signal detection, etc., which is expected to fuel the market growth over the forecasted period. For instance, Sanofi and Deloitte collaborated on ConvergeHEALTH Safety, a next-generation artificial intelligence (AI) software-as-a-service adverse events case intake platform that transformed pharmacovigilance (PV) processes and addressed some of the industry's most pressing operational safety issues. In line with this, ArisGlobal introduced the go-live of the USFDA Adverse Event Reporting System (FAERS II), an electronic safety reporting platform powered by LifeSphere MultiVigilance, which propelled the market growth. Furthermore, Saama Technologies Inc. developed the new Active Safety Analytics for Pharma (ASAP) products. ASAP is one of the first validated pharmacovigilance solutions to leverage the TreeScan methodology and the United States Food and Drug Administration's (FDA) Sentinel Common Data Model for detecting safety signals.

Stringent Regulations Implemented by Government Bodies

Government authorities across the globe are implementing strict rules in clinical trials and generating awareness regarding the proper utilization of medicines, which is stimulating the usage of pharmacovigilance services. For example, according to a study published in Frontiers in Drug Safety and Regulation, the significance of post-marketing medication evaluation is important for characterizing drug safety profiles in real-world settings. Such studies are further increasing the importance of pharmacovigilance, thereby stimulating the market growth. Moreover, Aurobindo Pharma USA reformulated Quinapril and Hydrochlorothiazide Tablets USP 20mg/12.5mg, owing to the presence of N-Nitroso-Quinapril and Nitrosamine Drug Substance Related Impurity (NDSRI). Consequently, the inflating need for medical information among regulatory authorities is expected to fuel the market growth over the forecasted period.

The Rising Adoption of Pharmacovigilance Services by Pharmaceutical Companies

Pharmacovigilance services are extensively adopted by key pharmaceutical companies across the globe, owing to benefits, such as better outcomes over shorter periods and increasing internal resource flexibility. For example, according to the Vaccine Adverse Event Reporting System, 10 cases of anaphylaxis were detected after the administration of a reported 4,041,396 first doses of the Moderna COVID-19 vaccine (2.5 cases per million doses). Consequently, the growing need for pharmacovigilance services is also stimulating the market growth. In addition to this, key industry players are also entering into strategic collaborations, which will continue to propel the pharmacovigilance market over the forecasted period. For example, IQVIA entered into a strategic collaboration with NRx Pharmaceuticals to offer medical information and pharmacovigilance services in preparation for potential regulatory actions.

The Growing Number of Advanced Clinical Trial Phases

To enhance the efficacy of clinical trials, major prominent players are developing advanced clinical trials, which are stimulating the global market for pharmacovigilance. For example, Cognizant entered into a partnership with Medable Inc. to jointly deliver clinical research solutions based on Medable's software-as-a-service platform for decentralized clinical trials. In line with this, according to the pharmacovigilance market overview, Viedoc and LINK Medical entered into a partnership established by Viedoc. The collaboration was designed to enhance trial efficiency for LINK Medical and its clients. The partnership allowed for the exchange of needs, experience, ideas, etc., and the testing of new features.

Pharmacovigilance Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global pharmacovigilance market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on service provider, product life cycle, type, process flow, therapeutic area, and end use.

Breakup by Service Provider:

In-house

Contract Outsourcing

The report has provided a detailed breakup and analysis of the market based on the service provider. This includes in-house and contract outsourcing.

Breakup by Product Life Cycle:

Pre-clinical

Phase I

Phase II

Phase III

Phase IV

A detailed breakup and analysis of the market based on the product life cycle has also been provided in the report. This includes pre-clinical, Phase I, Phase II, Phase III, and Phase IV.

Breakup by Type:

Spontaneous Reporting

Intensified ADR Reporting

Targeted Spontaneous Reporting

Cohort Event Monitoring

EHR Mining

The report has provided a detailed breakup and analysis of the market based on the type. This includes spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring, and EHR Mining.

Breakup by Process Flow:

Case Data Management

Case Logging

Case Data Analysis

Medical Reviewing and Reporting

Signal Detection

Adverse Event Logging

Adverse Event Analysis

Adverse Event Review and Reporting

Risk Management System

Risk Evaluation System

Risk Mitigation System

The report has provided a detailed breakup and analysis of the market based on the process flow. This includes case data management (case logging, case data analysis, medical reviewing and reporting), signal detection (adverse event logging, adverse event analysis, and adverse event review and reporting, and risk management system (risk evaluation system and risk mitigation system).

Breakup by Therapeutic Area:

Oncology

Neurology

Cardiology

Respiratory Systems

Others

The report has provided a detailed breakup and analysis of the market based on the therapeutic area. This includes oncology, neurology, cardiology, respiratory systems, and others.

Breakup by End Use:

Pharmaceuticals Companies

Biotechnology Companies

Medical Device Companies

Others

The report has provided a detailed breakup and analysis of the market based on the end-use. This includes pharmaceuticals companies, biotechnology companies, medical device companies, and others.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

Competitive Landscape:

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the pharmacovigilance top companies are listed below:

Accenture plc

ArisGlobal LLC

BioClinica Inc. (Cinven Partners LLP)

Capgemini

Cognizant

International Business Machines Corporation

ICON plc.

IQVIA Inc.

ITClinical

Parexel International Corporation

Wipro Limited

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Global Pharmacovigilance Market News:

March 2024: The American Society of Pharmacovigilance (ASP), along with several partners, is focused on advancing drug safety via minimizing ADEs, the fourth leading cause of death in the United States.

February 2024: The Indian Pharmacopoeia Commission (IPC) released the Draft Pharmacovigilance Guidance Document for pharmaceutical products for its latest Version 2.0. The Commission also offered suggestions from Marketing Authorization Holders (MAHs) on the draft document.

February 2024: The US Food and Drug Administration (FDA) Office of Surveillance and Epidemiology (OSE) launched the standardization of Risk Evaluation and Mitigation Strategies (REMS) data to facilitate its use.

Key Questions Answered in This Report:

  • How has the global pharmacovigilance market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global pharmacovigilance market?
  • What are the key regional markets?
  • What is the breakup of the market based on the service provider?
  • What is the breakup of the market based on the product life cycle?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the process flow?
  • What is the breakup of the market based on the therapeutic area?
  • What is the breakup of the market based on the end use?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global pharmacovigilance market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pharmacovigilance Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Service Provider

  • 6.1 In-house
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Contract Outsourcing
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Product Life Cycle

  • 7.1 Pre-clinical
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Phase I
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Phase II
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Phase III
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Phase IV
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Type

  • 8.1 Spontaneous Reporting
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Intensified ADR Reporting
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Targeted Spontaneous Reporting
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Cohort Event Monitoring
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 EHR Mining
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Process Flow

  • 9.1 Case Data Management
    • 9.1.1 Market Trends
    • 9.1.2 Major Types
      • 9.1.2.1 Case Logging
      • 9.1.2.2 Case Data Analysis
      • 9.1.2.3 Medical Reviewing and Reporting
    • 9.1.3 Market Forecast
  • 9.2 Signal Detection
    • 9.2.1 Market Trends
    • 9.2.2 Major Types
      • 9.2.2.1 Adverse Event Logging
      • 9.2.2.2 Adverse Event Analysis
      • 9.2.2.3 Adverse Event Review and Reporting
    • 9.2.3 Market Forecast
  • 9.3 Risk Management System
    • 9.3.1 Market Trends
    • 9.3.2 Major Types
      • 9.3.2.1 Risk Evaluation System
      • 9.3.2.2 Risk Mitigation System
    • 9.3.3 Market Forecast

10 Market Breakup by Therapeutic Area

  • 10.1 Oncology
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Neurology
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Cardiology
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Respiratory Systems
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Others
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 Market Breakup by End Use

  • 11.1 Pharmaceuticals Companies
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Biotechnology Companies
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast
  • 11.3 Medical Device Companies
    • 11.3.1 Market Trends
    • 11.3.2 Market Forecast
  • 11.4 Others
    • 11.4.1 Market Trends
    • 11.4.2 Market Forecast

12 Market Breakup by Region

  • 12.1 North America
    • 12.1.1 United States
      • 12.1.1.1 Market Trends
      • 12.1.1.2 Market Forecast
    • 12.1.2 Canada
      • 12.1.2.1 Market Trends
      • 12.1.2.2 Market Forecast
  • 12.2 Asia-Pacific
    • 12.2.1 China
      • 12.2.1.1 Market Trends
      • 12.2.1.2 Market Forecast
    • 12.2.2 Japan
      • 12.2.2.1 Market Trends
      • 12.2.2.2 Market Forecast
    • 12.2.3 India
      • 12.2.3.1 Market Trends
      • 12.2.3.2 Market Forecast
    • 12.2.4 South Korea
      • 12.2.4.1 Market Trends
      • 12.2.4.2 Market Forecast
    • 12.2.5 Australia
      • 12.2.5.1 Market Trends
      • 12.2.5.2 Market Forecast
    • 12.2.6 Indonesia
      • 12.2.6.1 Market Trends
      • 12.2.6.2 Market Forecast
    • 12.2.7 Others
      • 12.2.7.1 Market Trends
      • 12.2.7.2 Market Forecast
  • 12.3 Europe
    • 12.3.1 Germany
      • 12.3.1.1 Market Trends
      • 12.3.1.2 Market Forecast
    • 12.3.2 France
      • 12.3.2.1 Market Trends
      • 12.3.2.2 Market Forecast
    • 12.3.3 United Kingdom
      • 12.3.3.1 Market Trends
      • 12.3.3.2 Market Forecast
    • 12.3.4 Italy
      • 12.3.4.1 Market Trends
      • 12.3.4.2 Market Forecast
    • 12.3.5 Spain
      • 12.3.5.1 Market Trends
      • 12.3.5.2 Market Forecast
    • 12.3.6 Russia
      • 12.3.6.1 Market Trends
      • 12.3.6.2 Market Forecast
    • 12.3.7 Others
      • 12.3.7.1 Market Trends
      • 12.3.7.2 Market Forecast
  • 12.4 Latin America
    • 12.4.1 Brazil
      • 12.4.1.1 Market Trends
      • 12.4.1.2 Market Forecast
    • 12.4.2 Mexico
      • 12.4.2.1 Market Trends
      • 12.4.2.2 Market Forecast
    • 12.4.3 Others
      • 12.4.3.1 Market Trends
      • 12.4.3.2 Market Forecast
  • 12.5 Middle East and Africa
    • 12.5.1 Market Trends
    • 12.5.2 Market Breakup by Country
    • 12.5.3 Market Forecast

13 SWOT Analysis

  • 13.1 Overview
  • 13.2 Strengths
  • 13.3 Weaknesses
  • 13.4 Opportunities
  • 13.5 Threats

14 Value Chain Analysis

15 Porters Five Forces Analysis

  • 15.1 Overview
  • 15.2 Bargaining Power of Buyers
  • 15.3 Bargaining Power of Suppliers
  • 15.4 Degree of Competition
  • 15.5 Threat of New Entrants
  • 15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

  • 17.1 Market Structure
  • 17.2 Key Players
  • 17.3 Profiles of Key Players
    • 17.3.1 Accenture plc
      • 17.3.1.1 Company Overview
      • 17.3.1.2 Product Portfolio
      • 17.3.1.3 Financials
      • 17.3.1.4 SWOT Analysis
    • 17.3.2 ArisGlobal LLC
      • 17.3.2.1 Company Overview
      • 17.3.2.2 Product Portfolio
    • 17.3.3 BioClinica Inc. (Cinven Partners LLP)
      • 17.3.3.1 Company Overview
      • 17.3.3.2 Product Portfolio
      • 17.3.3.3 SWOT Analysis
    • 17.3.4 Capgemini
      • 17.3.4.1 Company Overview
      • 17.3.4.2 Product Portfolio
    • 17.3.5 Cognizant
      • 17.3.5.1 Company Overview
      • 17.3.5.2 Product Portfolio
      • 17.3.5.3 Financials
      • 17.3.5.4 SWOT Analysis
    • 17.3.6 International Business Machines Corporation
      • 17.3.6.1 Company Overview
      • 17.3.6.2 Product Portfolio
      • 17.3.6.3 Financials
      • 17.3.6.4 SWOT Analysis
    • 17.3.7 ICON plc.
      • 17.3.7.1 Company Overview
      • 17.3.7.2 Product Portfolio
      • 17.3.7.3 Financials
      • 17.3.7.4 SWOT Analysis
    • 17.3.8 IQVIA Inc.
      • 17.3.8.1 Company Overview
      • 17.3.8.2 Product Portfolio
      • 17.3.8.3 Financials
      • 17.3.8.4 SWOT Analysis
    • 17.3.9 ITClinical
      • 17.3.9.1 Company Overview
      • 17.3.9.2 Product Portfolio
    • 17.3.10 Parexel International Corporation
      • 17.3.10.1 Company Overview
      • 17.3.10.2 Product Portfolio
      • 17.3.10.3 SWOT Analysis
    • 17.3.11 Wipro Limited
      • 17.3.11.1 Company Overview
      • 17.3.11.2 Product Portfolio
      • 17.3.11.3 Financials
      • 17.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Pharmacovigilance Market: Major Drivers and Challenges
  • Figure 2: Global: Pharmacovigilance Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Pharmacovigilance Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Pharmacovigilance Market: Breakup by Service Provider (in %), 2023
  • Figure 5: Global: Pharmacovigilance Market: Breakup by Product Life Cycle (in %), 2023
  • Figure 6: Global: Pharmacovigilance Market: Breakup by Type (in %), 2023
  • Figure 7: Global: Pharmacovigilance Market: Breakup by Process Flow (in %), 2023
  • Figure 8: Global: Pharmacovigilance Market: Breakup by Therapeutic Area (in %), 2023
  • Figure 9: Global: Pharmacovigilance Market: Breakup by End Use (in %), 2023
  • Figure 10: Global: Pharmacovigilance Market: Breakup by Region (in %), 2023
  • Figure 11: Global: Pharmacovigilance (In-house) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Pharmacovigilance (In-house) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Pharmacovigilance (Contract Outsourcing) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Pharmacovigilance (Contract Outsourcing) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Pharmacovigilance (Pre-clinical) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Pharmacovigilance (Pre-clinical) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Pharmacovigilance (Phase I) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Pharmacovigilance (Phase I) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Pharmacovigilance (Phase II) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Pharmacovigilance (Phase II) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Pharmacovigilance (Phase III) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Pharmacovigilance (Phase III) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Pharmacovigilance (Phase IV) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Pharmacovigilance (Phase IV) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Pharmacovigilance (Spontaneous Reporting) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Pharmacovigilance (Spontaneous Reporting) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Pharmacovigilance (Intensified ADR Reporting) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Pharmacovigilance (Intensified ADR Reporting) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Pharmacovigilance (Targeted Spontaneous Reporting) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Pharmacovigilance (Targeted Spontaneous Reporting) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Pharmacovigilance (Cohort Event Monitoring) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Pharmacovigilance (Cohort Event Monitoring) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Pharmacovigilance (EHR Mining) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Pharmacovigilance (EHR Mining) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Pharmacovigilance (Case Data Management) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Pharmacovigilance (Case Data Management) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Pharmacovigilance (Signal Detection) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Pharmacovigilance (Signal Detection) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Pharmacovigilance (Risk Management System) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Pharmacovigilance (Risk Management System) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Global: Pharmacovigilance (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Global: Pharmacovigilance (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Global: Pharmacovigilance (Neurology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Global: Pharmacovigilance (Neurology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Global: Pharmacovigilance (Cardiology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Global: Pharmacovigilance (Cardiology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Global: Pharmacovigilance (Respiratory Systems) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Global: Pharmacovigilance (Respiratory Systems) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Global: Pharmacovigilance (Other Therapeutic Areas) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Global: Pharmacovigilance (Other Therapeutic Areas) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Global: Pharmacovigilance (Pharmaceuticals Companies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Global: Pharmacovigilance (Pharmaceuticals Companies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Global: Pharmacovigilance (Biotechnology Companies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Global: Pharmacovigilance (Biotechnology Companies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Global: Pharmacovigilance (Medical Device Companies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Global: Pharmacovigilance (Medical Device Companies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Global: Pharmacovigilance (Other End Uses) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Global: Pharmacovigilance (Other End Uses) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: North America: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: North America: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: United States: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: United States: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Canada: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Canada: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Asia-Pacific: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Asia-Pacific: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: China: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: China: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Japan: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Japan: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: India: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: India: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: South Korea: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: South Korea: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Australia: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Australia: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Indonesia: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Indonesia: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Others: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Others: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Europe: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Europe: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Germany: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Germany: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: France: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: France: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: United Kingdom: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: United Kingdom: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Italy: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 90: Italy: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 91: Spain: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 92: Spain: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 93: Russia: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 94: Russia: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 95: Others: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 96: Others: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 97: Latin America: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 98: Latin America: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 99: Brazil: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 100: Brazil: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 101: Mexico: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 102: Mexico: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 103: Others: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 104: Others: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 105: Middle East and Africa: Pharmacovigilance Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 106: Middle East and Africa: Pharmacovigilance Market: Breakup by Country (in %), 2023
  • Figure 107: Middle East and Africa: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 108: Global: Pharmacovigilance Industry: SWOT Analysis
  • Figure 109: Global: Pharmacovigilance Industry: Value Chain Analysis
  • Figure 110: Global: Pharmacovigilance Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pharmacovigilance Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Pharmacovigilance Market Forecast: Breakup by Service Provider (in Million US$), 2024-2032
  • Table 3: Global: Pharmacovigilance Market Forecast: Breakup by Product Life Cycle (in Million US$), 2024-2032
  • Table 4: Global: Pharmacovigilance Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 5: Global: Pharmacovigilance Market Forecast: Breakup by Process Flow (in Million US$), 2024-2032
  • Table 6: Global: Pharmacovigilance Market Forecast: Breakup by Therapeutic Area (in Million US$), 2024-2032
  • Table 7: Global: Pharmacovigilance Market Forecast: Breakup by End Use (in Million US$), 2024-2032
  • Table 8: Global: Pharmacovigilance Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 9: Global: Pharmacovigilance Market: Competitive Structure
  • Table 10: Global: Pharmacovigilance Market: Key Players